Prelude Therapeutics
Clinical trials sponsored by Prelude Therapeutics, explained in plain language.
-
New hope for tough blood cancers: experimental drug PRT2527 enters human testing
Disease control CompletedThis early-stage trial tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to check safety, find the best dose, and see if th…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in people with advanced cancers that have a specific change in the SMARCA4 gene. The goal was to find a safe dose and see if the drug shrinks tumors. The study included 135 adults who…
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC